Hot Features
プレミアム
Veracyte Inc (VCYT)
NASDAQ
登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。
| 日付 | 保有者名 | 取引株数 | 金額レンジ ($) | 取引種別 | 価格レンジ ($) | 届出終了時の株数 | % 変化 |
|---|---|---|---|---|---|---|---|
| 2026-05-22 | Mr. Jonathan WygantVP & CAO | -24.00k | 494.42k | Derivative Exercise and Sale | 24.80 - 45.40 | 7.87k | - |
| 2026-05-20 | Dr. Robert S. EpsteinIndependent Chair | -10.00k | 440.13k | Automatic Disposition | 44.01 | 43.13k | -18.82% |
| 2026-05-06 | Ms. Annie McGuireExec. VP, General Counsel & Head of Market Access | -10.20k | 398.21k | Automatic Disposition | 38.05 - 40.00 | 1.13k | -90.02% |
| 2026-03-04 | Ms. Annie McGuireExec. VP, General Counsel & Head of Market Access | -6.66k | 236.72k | Automatic Disposition | 35.29 - 36.34 | 11.34k | -37.00% |
| 2026-03-04 | Ms. Rebecca ChambersExec. VP & CFO | -18.34k | 662.87k | Automatic Disposition | 35.55 - 36.33 | 36.20k | -33.63% |
| 2026-03-04 | Mr. Marc A. StapleyCEO & Director | -45.52k | 1.64M | Automatic Disposition | 35.56 - 36.28 | 143.90k | -24.03% |
| 2026-03-04 | Dr. John LeiteGlobal Chief Commercial Officer | -5.26k | 185.08k | Automatic Disposition | 35.19 | 18.38k | -22.25% |
| 2026-03-02 | Mr. Marc A. StapleyCEO & Director | -19.46k | 700.57k | Sale to Issuer | 36.01 | 189.42k | -9.31% |
| 2026-03-02 | Dr. Phillip G. FebboChief Scientific & Medical Officer | -13.43k | 485.43k | Automatic Disposition | 36.16 | 32.06k | -29.51% |
| 2026-03-02 | Dr. Phillip G. FebboChief Scientific & Medical Officer | -6.04k | 217.32k | Sale to Issuer | 36.01 | 32.06k | -15.84% |
| 2026-03-02 | Dr. John LeiteGlobal Chief Commercial Officer | -7.52k | 270.69k | Sale to Issuer | 36.01 | 23.64k | -24.13% |
| 2026-03-02 | Ms. Rebecca ChambersExec. VP & CFO | -7.23k | 260.50k | Sale to Issuer | 36.01 | 54.54k | -11.71% |
| 2026-03-02 | Ms. Annie McGuireExec. VP, General Counsel & Head of Market Access | -6.90k | 248.54k | Sale to Issuer | 36.01 | 17.99k | -27.72% |
| 2026-03-02 | Mr. Jonathan WygantVP & CAO | -3.01k | 108.25k | Sale to Issuer | 36.01 | 7.87k | -27.64% |
| 2026-02-26 | Dr. Phillip G. FebboChief Scientific & Medical Officer | -24.49k | 948.83k | Sale to Issuer | 38.75 | 39.67k | -38.17% |
| 2026-02-26 | Ms. Rebecca ChambersExec. VP & CFO | -12.05k | 466.90k | Sale to Issuer | 38.75 | 47.56k | -20.21% |
| 2026-02-26 | Dr. John LeiteGlobal Chief Commercial Officer | -8.91k | 345.07k | Sale to Issuer | 38.75 | 16.39k | -35.21% |
| 2026-02-26 | Mr. Marc A. StapleyCEO & Director | -35.84k | 1.39M | Sale to Issuer | 38.75 | 170.64k | -17.36% |
| 2026-02-26 | Ms. Annie McGuireExec. VP, General Counsel & Head of Market Access | -10.87k | 421.10k | Sale to Issuer | 38.75 | 11.34k | -48.94% |
| 2025-12-16 | Ms. Annie McGuireExec. VP, General Counsel & Head of Market Access | -10.74k | 463.20k | Automatic Disposition | 43.13 - 43.68 | 758.00 | -93.41% |
| 2025-12-05 | Ms. Karin EasthamIndependent Director | -20.00k | 753.52k | Derivative Exercise and Sale | 7.60 - 46.59 | 4.23k | - |
| 2025-12-04 | Mr. Marc A. StapleyCEO & Director | -7.67k | 361.08k | Automatic Disposition | 46.90 - 47.35 | 135.55k | -5.35% |
| 2025-12-02 | Mr. Marc A. StapleyCEO & Director | -7.91k | 365.31k | Sale to Issuer | 46.16 | 135.55k | -5.52% |
| 2025-12-02 | Dr. Phillip G. FebboChief Scientific & Medical Officer | -2.96k | 136.40k | Sale to Issuer | 46.16 | 16.29k | -15.36% |
| 2025-12-02 | Mr. Jonathan WygantVP & CAO | -1.33k | 61.16k | Sale to Issuer | 46.16 | 4.26k | -23.74% |
| 2025-12-04 | Ms. Rebecca ChambersExec. VP & CFO | -13.28k | 621.96k | Automatic Disposition | 46.61 - 47.25 | 36.20k | -26.84% |
| 2025-12-02 | Ms. Rebecca ChambersExec. VP & CFO | -3.38k | 156.21k | Sale to Issuer | 46.16 | 36.20k | -8.55% |
| 2025-12-04 | Ms. Annie McGuireExec. VP, General Counsel & Head of Market Access | -1.42k | 67.26k | Automatic Disposition | 47.10 - 47.51 | 11.50k | -11.01% |
| 2025-12-02 | Ms. Annie McGuireExec. VP, General Counsel & Head of Market Access | -3.05k | 140.88k | Sale to Issuer | 46.16 | 11.50k | -20.98% |
| 2025-12-04 | Dr. John LeiteGlobal Chief Commercial Officer | -1.28k | 60.72k | Automatic Disposition | 47.51 | 8.07k | -13.67% |
| 2025-12-02 | Dr. John LeiteGlobal Chief Commercial Officer | -2.90k | 133.86k | Sale to Issuer | 46.16 | 8.07k | -26.44% |
| 2025-11-25 | Dr. John LeiteGlobal Chief Commercial Officer | -2.81k | 140.40k | Automatic Disposition | 50.00 | 6.54k | -30.04% |
| 2025-11-25 | Mr. Evan JonesIndependent Director | -1.11k | 55.58k | Automatic Disposition | 50.25 | 20.04k | -5.23% |
| 2025-11-20 | Mr. Jens H. HolsteinIndependent Director | -10.00k | 423.56k | Automatic Disposition | 40.95 - 43.21 | 17.88k | -35.87% |
| 2025-11-07 | Mr. Jonathan WygantVP & CAO | -10.92k | 449.91k | 売り | 40.21 - 42.33 | 2.78k | -79.70% |
| 2025-11-05 | Ms. Annie McGuireExec. VP, General Counsel & Head of Market Access | -6.47k | 258.64k | Automatic Disposition | 40.00 | 9.96k | -39.36% |
| 2025-11-05 | Mr. Evan JonesIndependent Director | -30.00k | 1.13M | Derivative Exercise and Sale | 5.28 - 45.73 | 21.15k | - |
| 2025-11-05 | Mr. Evan JonesIndependent Director | -13.20k | 603.84k | Automatic Disposition | 45.73 - 46.38 | 21.15k | -38.42% |
| 2025-11-05 | Ms. Karin EasthamIndependent Director | -9.67k | 387.19k | Automatic Disposition | 40.02 | 4.23k | -69.56% |
| 2025-11-05 | Ms. Rebecca ChambersExec. VP & CFO | -7.00k | 287.00k | Automatic Disposition | 41.00 | 46.20k | -13.16% |
| 2025-10-06 | Dr. Phillip G. FebboChief Scientific & Medical Officer | -8.35k | 300.71k | Automatic Disposition | 36.02 | 13.43k | -38.34% |
| 2025-10-01 | Ms. Annie McGuireExec. VP, General Counsel & Head of Market Access | -2.16k | 75.61k | Automatic Disposition | 35.00 | 16.43k | -11.62% |
| 2025-10-01 | Dr. Robert S. EpsteinIndependent Chair | -10.00k | 271.37k | Derivative Exercise and Sale | 7.94 - 35.08 | 53.13k | - |
| 2025-10-01 | Dr. Robert S. EpsteinIndependent Chair | -11.47k | 402.44k | Automatic Disposition | 35.08 | 53.13k | -17.76% |
| 2025-10-01 | Dr. John LeiteGlobal Chief Commercial Officer | -2.54k | 88.87k | Automatic Disposition | 35.00 | 9.35k | -21.36% |
| 2025-09-19 | Ms. Annie McGuireExec. VP, General Counsel & Head of Market Access | -2.28k | 76.92k | Automatic Disposition | 33.69 | 18.59k | -10.94% |
| 2025-09-04 | Mr. Marc A. StapleyCEO & Director | -7.67k | 233.13k | Automatic Disposition | 30.41 | 135.55k | -5.35% |
| 2025-09-02 | Ms. Rebecca ChambersExec. VP & CFO | -5.37k | 161.72k | Sale to Issuer | 30.11 | 53.20k | -9.17% |
| 2025-09-02 | Ms. Annie McGuireExec. VP, General Counsel & Head of Market Access | -3.51k | 105.60k | Sale to Issuer | 30.11 | 20.87k | -14.39% |
| 2025-09-02 | Mr. Marc A. StapleyCEO & Director | -7.91k | 238.29k | Sale to Issuer | 30.11 | 143.22k | -5.24% |
| 2025-09-02 | Dr. Phillip G. FebboChief Scientific & Medical Officer | -2.96k | 88.98k | Sale to Issuer | 30.11 | 21.78k | -11.95% |
| 2025-09-02 | Dr. John LeiteGlobal Chief Commercial Officer | -2.90k | 87.38k | Sale to Issuer | 30.11 | 11.89k | -19.62% |
| 2025-09-02 | Mr. Jonathan WygantVP & CAO | -1.65k | 49.62k | Sale to Issuer | 30.11 | 13.70k | -10.74% |
| 2025-06-13 | Ms. Karin EasthamIndependent Director | -4.59k | 122.39k | Automatic Disposition | 26.66 | 13.91k | -24.81% |
| 2025-06-13 | Ms. Muna BhanjiIndependent Director | -4.59k | 122.37k | Automatic Disposition | 26.67 | 29.99k | -13.27% |
| 2025-06-04 | Dr. John LeiteGlobal Chief Commercial Officer | -2.81k | 76.41k | Automatic Disposition | 27.20 | 9.08k | -23.63% |
ご覧いただいた銘柄が下記のボックス内に表示されますので、過去閲覧した銘柄情報に簡単にアクセスすることができます。
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約
メールアドレスで登録
すでにアカウントをお持ちですか？ サインイン
アカウントをお持ちでないですか？ 登録
登録することで、ADVFN の 利用規約 を読み、理解し、同意したこと、および私が個人投資家であることを確認します。
